---------------------------- 2023 Platform Presentation Winner --------------------------

 

Molecular Landscape and Clinical Behavior of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Lisa Vermij, Amy Jamieson, Joseph Carlson, Brooke Howitt, Philip Ip, Sigurd Lax, Glenn McCluggage, Naveena Singh, Remi Nout, Carien Creutzberg, Nanda Horeweg, Tjalling Bosse, C. Blake Gilks

Background: The clinical significance of applying the TCGA molecular classification in stage I low-grade endometrial endometrioid carcinoma (EEC) is under debate as these patients generally have an excellent clinical outcome. However, a small subset of stage I low-grade EEC are p53-abnormal (p53abn) and may have a poor prognosis, although their existence is questioned. Here, we aimed to pathologically review and characterize stage I low-grade p53abn EEC previously identified in our databases.

Design: Tumor material from the PORTEC-1 and -2 trials (n=881) and retrospectively collected Canadian historic cohorts (n=2506) was available for analysis. All patients with previously reported stage I p53abn EEC were selected; none of these exhibited pathogenic POLE mutations or mismatch repair-deficiency. Abnormal p53 status was confirmed by p53  Tue, March 14  9:00 AM - 9:15 AM  CC Room 217 immunohistochemistry (IHC) and TP53 mutation analysis. Review of histotype and FIGO grading was performed by six expert gynecological pathologists, blinded to the molecular subgroup and study aim, using one H&E-stained section per case. Low-grade NSMP EEC (n=10) and p53abn serous carcinomas (n=13) were included as controls. The mutational landscape was assessed with next generation sequencing. The Kaplan-Meier method was used for the assessment of recurrence-free survival (RFS).

Results: In total, 55 p53abn stage I low-grade EEC were identified. Following pathology review, 17 (30.9%) cases were assigned as not low-grade EEC by all of the expert pathologists, while 38 (69.1%) and 26 (47.3%) were assigned low-grade EEC by ≥1 and ≥3 pathologists, respectively. Two representative cases are illustrated in figure 1. Clustering cases by agreement on lowgrade EEC histology showed no significant differences in mutational landscape, with a low prevalence of PTEN and PIK3CA mutations in all cases (figure 2). 5-year RFS was higher with increasing agreement on low-grade EEC histology, with a 5-year RFS of 61.9%, 72.8% and 76.5% for cases assigned as low-grade EEC by none, ≥1 and ≥3 pathologists, respectively.



Conclusions: A subset of p53abn endometrial carcinomas are morphologically low-grade endometrioid with a molecular landscape that is similar to prototypical p53abn endometrial carcinomas. The risk of recurrence for patients with stage I low-grade p53abn EEC is higher compared to the risk of recurrence of stage I low-grade EEC in literature. Our results may support performing molecular classification on all endometrial carcinomas.

 


Chat With ISGYP

close
First Name *
Last Name *
Email *
Customer ID